CAJ | 학술논문

目前临床上应用的抗HBV治疗药物主要有两类：干扰素和核苷（酸）类似物，前者不良反应较大，后者存在病毒耐药问题。抗HBV药物最大的问题是大多数患者在长期治疗后仍不能彻底清除病毒。因此，研发针对HBV不同靶位的新药对慢性HBV感染性疾病的治疗意义重大。本文就抗HBV药物靶位的研究进展进行综述。
목전림상상응용적항HBV치료약물주요유량류：간우소화핵감（산）유사물，전자불량반응교대，후자존재병독내약문제。항HBV약물최대적문제시대다수환자재장기치료후잉불능철저청제병독。인차，연발침대HBV불동파위적신약대만성HBV감염성질병적치료의의중대。본문취항HBV약물파위적연구진전진행종술。
The most commonly-used antiviral agents for HBV have been divided into two categories:interferons and nucleos(t)-ide analogues. The former has the limitation of multiple side effects, while the later is characterized by the problem of drug resis-tance. The major problem is that most patients cannot eradicate viruses through long-term antiviral therapies. Therefore, it is impor-tant to develop potent agents against various viral targets for the management of chronic HBV infectious diseases. This review focus-es on the recent progress in viral targets for anti-HBV agents.